Peringatan Keamanan

There is currently no data for imlifidase administered at supra-therapeutic doses; therefore, toxicity information is not readily available.^L28001 In cases of overdose, the patient should be carefully monitored and symptomatic treatment should be initiated as needed.^L28001 Although there is no antidote to imlifidase, administration of intravenous IgG may correct depleted IgG levels.^L28001

Imlifidase

DB15258

biotech approved investigational

Deskripsi

Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large.^A225916 Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.A225836,A225916

Patients who have developed human leukocyte antigen (HLA) sensitization from prior exposure to blood products, pregnancy, or any other circumstance which may have resulted in exposure to non-self HLA antigens, face additional barriers to transplantation.A225836,A225921 Highly sensitized individuals carry high levels of anti-HLA antibodies and are at significant risk for antibody-mediated rejection which occurs mainly through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).^A225836 High levels of anti-HLA antibodies also contribute to poor graft survival.^A225836 As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft.A225836,A225921

Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.^L28001 As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation in highly sensitized patients to proceed.A225836,L28001

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean distribution half-life of imlifidase is reported to be 1.8 hours, while the mean elimination half-life is reported to be 89 hours.[A225836]

Volume Distribusi The volume of distribution of imlifidase is reported to be 0.2 L/kg in the elimination phase.[A225836]

Klirens (Clearance) The mean clearance value of imlifidase is reported to be 1.8 mL/h/kg.[A225836]

Absorpsi

Given that imlifidase is administered intravenously, it is fully absorbed and bioavailable; imlifidase exposure is dose-proportional and predictable.A225836,L28001 After a dose of 0.25 mg/kg, the mean Cmax of imlifidase was 5.8 (4.2-8.9) ug/mL.^L28001 Tmax occurs once infusion is complete or soon after.^A225836 Food is not expected to impact the effectiveness or absorption of imlifidase.^L28001

Metabolisme

There is currently no imlifidase metabolism data available; however, it is thought to be eliminated via proteolysis.^L28041

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

194 Data

Human immunoglobulin G	The therapeutic efficacy of Imlifidase can be decreased when used in combination with Human immunoglobulin G.
Cetuximab	The therapeutic efficacy of Cetuximab can be decreased when used in combination with Imlifidase.
Omalizumab	The therapeutic efficacy of Omalizumab can be decreased when used in combination with Imlifidase.
Adalimumab	The therapeutic efficacy of Adalimumab can be decreased when used in combination with Imlifidase.
Abciximab	The therapeutic efficacy of Abciximab can be decreased when used in combination with Imlifidase.
Gemtuzumab ozogamicin	The therapeutic efficacy of Gemtuzumab ozogamicin can be decreased when used in combination with Imlifidase.
Infliximab	The therapeutic efficacy of Infliximab can be decreased when used in combination with Imlifidase.
Trastuzumab	The therapeutic efficacy of Trastuzumab can be decreased when used in combination with Imlifidase.
Rituximab	The therapeutic efficacy of Rituximab can be decreased when used in combination with Imlifidase.
Basiliximab	The therapeutic efficacy of Basiliximab can be decreased when used in combination with Imlifidase.
Muromonab	The therapeutic efficacy of Muromonab can be decreased when used in combination with Imlifidase.
Alemtuzumab	The therapeutic efficacy of Alemtuzumab can be decreased when used in combination with Imlifidase.
Efalizumab	The therapeutic efficacy of Efalizumab can be decreased when used in combination with Imlifidase.
Natalizumab	The therapeutic efficacy of Natalizumab can be decreased when used in combination with Imlifidase.
Palivizumab	The therapeutic efficacy of Palivizumab can be decreased when used in combination with Imlifidase.
Daclizumab	The therapeutic efficacy of Daclizumab can be decreased when used in combination with Imlifidase.
Bevacizumab	The therapeutic efficacy of Bevacizumab can be decreased when used in combination with Imlifidase.
Panitumumab	The therapeutic efficacy of Panitumumab can be decreased when used in combination with Imlifidase.
Ranibizumab	The therapeutic efficacy of Ranibizumab can be decreased when used in combination with Imlifidase.
Pexelizumab	The therapeutic efficacy of Pexelizumab can be decreased when used in combination with Imlifidase.
Epratuzumab	The therapeutic efficacy of Epratuzumab can be decreased when used in combination with Imlifidase.
Labetuzumab	The therapeutic efficacy of Labetuzumab can be decreased when used in combination with Imlifidase.
Matuzumab	The therapeutic efficacy of Matuzumab can be decreased when used in combination with Imlifidase.
Fontolizumab	The therapeutic efficacy of Fontolizumab can be decreased when used in combination with Imlifidase.
Otelixizumab	The therapeutic efficacy of Otelixizumab can be decreased when used in combination with Imlifidase.
Enokizumab	The therapeutic efficacy of Enokizumab can be decreased when used in combination with Imlifidase.
Ramucirumab	The therapeutic efficacy of Ramucirumab can be decreased when used in combination with Imlifidase.
Farletuzumab	The therapeutic efficacy of Farletuzumab can be decreased when used in combination with Imlifidase.
Veltuzumab	The therapeutic efficacy of Veltuzumab can be decreased when used in combination with Imlifidase.
Ustekinumab	The therapeutic efficacy of Ustekinumab can be decreased when used in combination with Imlifidase.
Trastuzumab emtansine	The therapeutic efficacy of Trastuzumab emtansine can be decreased when used in combination with Imlifidase.
TNX-901	The therapeutic efficacy of TNX-901 can be decreased when used in combination with Imlifidase.
Inotuzumab ozogamicin	The therapeutic efficacy of Inotuzumab ozogamicin can be decreased when used in combination with Imlifidase.
RI 624	The therapeutic efficacy of RI 624 can be decreased when used in combination with Imlifidase.
Leronlimab	The therapeutic efficacy of Leronlimab can be decreased when used in combination with Imlifidase.
Olaratumab	The therapeutic efficacy of Olaratumab can be decreased when used in combination with Imlifidase.
Eldelumab	The therapeutic efficacy of Eldelumab can be decreased when used in combination with Imlifidase.
Ipilimumab	The therapeutic efficacy of Ipilimumab can be decreased when used in combination with Imlifidase.
Nimotuzumab	The therapeutic efficacy of Nimotuzumab can be decreased when used in combination with Imlifidase.
Tocilizumab	The therapeutic efficacy of Tocilizumab can be decreased when used in combination with Imlifidase.
Motavizumab	The therapeutic efficacy of Motavizumab can be decreased when used in combination with Imlifidase.
Elotuzumab	The therapeutic efficacy of Elotuzumab can be decreased when used in combination with Imlifidase.
AVE9633	The therapeutic efficacy of AVE9633 can be decreased when used in combination with Imlifidase.
XmAb 2513	The therapeutic efficacy of XmAb 2513 can be decreased when used in combination with Imlifidase.
Coltuximab ravtansine	The therapeutic efficacy of Coltuximab ravtansine can be decreased when used in combination with Imlifidase.
Lucatumumab	The therapeutic efficacy of Lucatumumab can be decreased when used in combination with Imlifidase.
Pertuzumab	The therapeutic efficacy of Pertuzumab can be decreased when used in combination with Imlifidase.
Siplizumab	The therapeutic efficacy of Siplizumab can be decreased when used in combination with Imlifidase.
Apolizumab	The therapeutic efficacy of Apolizumab can be decreased when used in combination with Imlifidase.
Sibrotuzumab	The therapeutic efficacy of Sibrotuzumab can be decreased when used in combination with Imlifidase.
Bivatuzumab	The therapeutic efficacy of Bivatuzumab can be decreased when used in combination with Imlifidase.
Reslizumab	The therapeutic efficacy of Reslizumab can be decreased when used in combination with Imlifidase.
Teplizumab	The therapeutic efficacy of Teplizumab can be decreased when used in combination with Imlifidase.
Catumaxomab	The therapeutic efficacy of Catumaxomab can be decreased when used in combination with Imlifidase.
Mepolizumab	The therapeutic efficacy of Mepolizumab can be decreased when used in combination with Imlifidase.
Denosumab	The therapeutic efficacy of Denosumab can be decreased when used in combination with Imlifidase.
Ofatumumab	The therapeutic efficacy of Ofatumumab can be decreased when used in combination with Imlifidase.
Golimumab	The therapeutic efficacy of Golimumab can be decreased when used in combination with Imlifidase.
Brentuximab vedotin	The therapeutic efficacy of Brentuximab vedotin can be decreased when used in combination with Imlifidase.
Belimumab	The therapeutic efficacy of Belimumab can be decreased when used in combination with Imlifidase.
Obinutuzumab	The therapeutic efficacy of Obinutuzumab can be decreased when used in combination with Imlifidase.
Vedolizumab	The therapeutic efficacy of Vedolizumab can be decreased when used in combination with Imlifidase.
Nivolumab	The therapeutic efficacy of Nivolumab can be decreased when used in combination with Imlifidase.
Pembrolizumab	The therapeutic efficacy of Pembrolizumab can be decreased when used in combination with Imlifidase.
Blinatumomab	The therapeutic efficacy of Blinatumomab can be decreased when used in combination with Imlifidase.
Dinutuximab	The therapeutic efficacy of Dinutuximab can be decreased when used in combination with Imlifidase.
Idarucizumab	The therapeutic efficacy of Idarucizumab can be decreased when used in combination with Imlifidase.
Alirocumab	The therapeutic efficacy of Alirocumab can be decreased when used in combination with Imlifidase.
Evolocumab	The therapeutic efficacy of Evolocumab can be decreased when used in combination with Imlifidase.
Daratumumab	The therapeutic efficacy of Daratumumab can be decreased when used in combination with Imlifidase.
Necitumumab	The therapeutic efficacy of Necitumumab can be decreased when used in combination with Imlifidase.
Ixekizumab	The therapeutic efficacy of Ixekizumab can be decreased when used in combination with Imlifidase.
Ravulizumab	The therapeutic efficacy of Ravulizumab can be decreased when used in combination with Imlifidase.
Atezolizumab	The therapeutic efficacy of Atezolizumab can be decreased when used in combination with Imlifidase.
Durvalumab	The therapeutic efficacy of Durvalumab can be decreased when used in combination with Imlifidase.
Bapineuzumab	The therapeutic efficacy of Bapineuzumab can be decreased when used in combination with Imlifidase.
Depatuxizumab mafodotin	The therapeutic efficacy of Depatuxizumab mafodotin can be decreased when used in combination with Imlifidase.
Solanezumab	The therapeutic efficacy of Solanezumab can be decreased when used in combination with Imlifidase.
Sarilumab	The therapeutic efficacy of Sarilumab can be decreased when used in combination with Imlifidase.
Brodalumab	The therapeutic efficacy of Brodalumab can be decreased when used in combination with Imlifidase.
Emibetuzumab	The therapeutic efficacy of Emibetuzumab can be decreased when used in combination with Imlifidase.
Ligelizumab	The therapeutic efficacy of Ligelizumab can be decreased when used in combination with Imlifidase.
Landogrozumab	The therapeutic efficacy of Landogrozumab can be decreased when used in combination with Imlifidase.
Vadastuximab talirine	The therapeutic efficacy of Vadastuximab talirine can be decreased when used in combination with Imlifidase.
Avelumab	The therapeutic efficacy of Avelumab can be decreased when used in combination with Imlifidase.
Ocrelizumab	The therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Imlifidase.
Benralizumab	The therapeutic efficacy of Benralizumab can be decreased when used in combination with Imlifidase.
Visilizumab	The therapeutic efficacy of Visilizumab can be decreased when used in combination with Imlifidase.
Gevokizumab	The therapeutic efficacy of Gevokizumab can be decreased when used in combination with Imlifidase.
Simtuzumab	The therapeutic efficacy of Simtuzumab can be decreased when used in combination with Imlifidase.
Fasinumab	The therapeutic efficacy of Fasinumab can be decreased when used in combination with Imlifidase.
Dupilumab	The therapeutic efficacy of Dupilumab can be decreased when used in combination with Imlifidase.
Etrolizumab	The therapeutic efficacy of Etrolizumab can be decreased when used in combination with Imlifidase.
Etaracizumab	The therapeutic efficacy of Etaracizumab can be decreased when used in combination with Imlifidase.
Aducanumab	The therapeutic efficacy of Aducanumab can be decreased when used in combination with Imlifidase.
Labetuzumab govitecan	The therapeutic efficacy of Labetuzumab govitecan can be decreased when used in combination with Imlifidase.
Tanezumab	The therapeutic efficacy of Tanezumab can be decreased when used in combination with Imlifidase.
Bococizumab	The therapeutic efficacy of Bococizumab can be decreased when used in combination with Imlifidase.
Mirvetuximab soravtansine	The therapeutic efficacy of Mirvetuximab Soravtansine can be decreased when used in combination with Imlifidase.
Mogamulizumab	The therapeutic efficacy of Mogamulizumab can be decreased when used in combination with Imlifidase.

Target Protein

IgG heavy chain IGHG1

Referensi & Sumber

Artikel (PubMed)

PMID: 33058042
Al-Salama ZT: Imlifidase: First Approval. Drugs. 2020 Nov;80(17):1859-1864. doi: 10.1007/s40265-020-01418-5.
PMID: 27822135
Fraser SD, Blakeman T: Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016 Aug 17;7:21-32. doi: 10.2147/POR.S97310. eCollection 2016.
PMID: 25062962
Rees L, Kim JJ: HLA sensitisation: can it be prevented? Pediatr Nephrol. 2015 Apr;30(4):577-87. doi: 10.1007/s00467-014-2868-6. Epub 2014 Jul 26.
PMID: 29561066
Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, Jarnum S, Stenberg Y, Robertson AK, Mosen K, Bjorck L, Backman L, Larsson E, Wood K, Tufveson G, Kjellman C: Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733. Epub 2018 Apr 17.
PMID: 26177518
Winstedt L, Jarnum S, Nordahl EA, Olsson A, Runstrom A, Bockermann R, Karlsson C, Malmstrom J, Palmgren GS, Malmqvist U, Bjorck L, Kjellman C: Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity. PLoS One. 2015 Jul 15;10(7):e0132011. doi: 10.1371/journal.pone.0132011. eCollection 2015.

Link

Contoh Produk & Brand

Produk: 2 • International brands: 1

Produk

Idefirix

Injection, powder, for solution • 11 mg • Intravenous • EU • Approved
Idefirix

Injection • 11 mg • Intravenous • EU • Approved

International Brands

Idefirix

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.